Category: Approval/Launch Region: Europe · United Kingdom Company: Astrazeneca Ltd

EU approves AstraZeneca and Daiichi Sankyo Enhertu to treat patients with unresectable or metastatic HER2-low metastatic breast cancer

EU approves AstraZeneca and Daiichi Sankyo Enhertu to treat patients with unresectable or metastatic HER2-low metastatic breast cancer
AstraZeneca and Daiichi Sankyo

Found this useful? Share it with your team.

Welcome Back Sign in to Continue

Don't Have an Account? Sign Up!
Forgot Password?

Create your Account!

Don't Have an Account? Sign Up!